APA (7th ed.) Citation

Gordon, K. B., Foley, P., Krueger, J. G., Pinter, A., Reich, K., Vender, R., . . . Blauvelt, A. (2021). Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet, 397(10273), 475. https://doi.org/10.1016/S0140-6736(21)00126-4

Chicago Style (17th ed.) Citation

Gordon, Kenneth B., et al. "Bimekizumab Efficacy and Safety in Moderate to Severe Plaque Psoriasis (BE READY): A Multicentre, Double-blind, Placebo-controlled, Randomised Withdrawal Phase 3 Trial." Lancet 397, no. 10273 (2021): 475. https://doi.org/10.1016/S0140-6736(21)00126-4.

MLA (9th ed.) Citation

Gordon, Kenneth B., et al. "Bimekizumab Efficacy and Safety in Moderate to Severe Plaque Psoriasis (BE READY): A Multicentre, Double-blind, Placebo-controlled, Randomised Withdrawal Phase 3 Trial." Lancet, vol. 397, no. 10273, 2021, p. 475, https://doi.org/10.1016/S0140-6736(21)00126-4.